Imvax, Inc., a biotechnology company specializing in personalized immunotherapies derived from whole tumors, has successfully enrolled participants in its Phase 2b clinical trial for IGV-001, designed for patients with newly diagnosed glioblastoma (ndGBM). IGV-001, developed from Imvax’s Goldspire™ immuno-oncology platform, aims to stimulate a robust and sustained immune response against tumors using the patient's own tumor cells. This trial, which is randomized, multicenter, double-blind, and placebo-controlled, has Progression-Free Survival (PFS) as its primary endpoint, with the release of top-line data anticipated by mid-2025.

Furthermore, the FDA has granted Fast Track designation to IGV-001 for ndGBM treatment based on encouraging Phase 1b results. Imvax also closed a financing round, securing approximately $35 million, with half of the funds coming from new investors. This brings the total raised over the past 15 months to $57 million, supporting the Phase 2b trial.

John P. Furey, Imvax's CEO, expressed appreciation for the rapid enrollment and the FDA's Fast Track designation, underscoring the critical need for innovative GBM treatments. The Phase 2b trial, involving around 100 participants, employs an autologous biologic-device combination product implanted post-surgery. Key secondary endpoints include overall survival (OS) and safety.

IGV-001, an autologous biologic-device combination, has demonstrated promise in Phase 1 studies, with notable improvements in PFS and OS observed in ndGBM patients. The FDA's Fast Track designation streamlines the review process for treatments addressing unmet medical needs, potentially leading to expedited approval.

Imvax's progress reflects its dedication to advancing treatment options for GBM patients, with sufficient resources now available to complete the trial and proceed towards potential regulatory approval.

 

Source: businesswire.com

Report Abuse